ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1163

A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects

Ahmet Gul1, Sibel Ulker2, Recep Selim Senturk2, Ugur Onsel Turk2, Cemil Gurgun2, Yan Lavrovsky3, Mikhail Samsonov4, Sebnem Ozen5 and Serdar Altinel6, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Ege University Drug Development and Pharmacokinetics Research and Application Centre (ARGEFAR), Izmir, Turkey, 3R-Pharm Overseas, Inc.,, San Diego, CA, 4Medical Department, R-Pharm JSC, Moscow, Russian Federation, 5Clinical Trial Department, TRPHARM İlac A.S., Istanbul, Turkey, 6linical Trial Department, TRPHARM İlac A.S., Istanbul, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologics, IL-1, monoclonal antibodies, pharmacokinetics and safety

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin-1 (IL-1) is highly active pro-inflammatory cytokine, which is responsible for clinical and laboratory findings in hereditary and acquired auto-inflammatory disorders. Blocking IL-1 activity in these conditions results in a rapid and sustained reduction in inflammatory activity and disease severity. RPH-104, a novel heterodimeric fusion protein containing IL-1R1 and IL-1RAcP linked to immunoglobulin heavy chains, highly selectively binds IL-1β, but can also bind IL-1α and IL-1Ra with lower affinity.  In this First-in-Human study, we aimed to evaluate safety as well as pharmacokinetic (PK) and pharmacodynamic (PD) parameters of RPH-104. Methods: A total of 35 healthy volunteers (HV) were enrolled in this randomized, double-blind, placebo-controlled, single-dose study. Five different dosages (4 mg, 20 mg, 40 mg, 80 mg and 160 mg) were tested in cohorts consisted of 7 HV in each. Each HV was hospitalized for 72 hours and followed up to 60 days after subcutaneous (SC) injection of RPH-104. Evaluation of safety data after each subgroup was performed by the Independent Data Monitoring Committee; and the next subgroup could be dosed when the previous dose results did not reveal any risk safety concern. Results: Totally 35 HV were dosed, 5 HV were administered RPH104 and 2 HV were administered placebo (saline) in each cohort; All 35 HV were included in the safety analysis but 33 HV were included in PK analysis (2 drop outs). Totally 70 adverse events (AE) were reported, none of them were serious. None of the AE was related to the study drug nor leaded to subject withdrawal. All AE were of mild intensity. RPH-104 was safe and well tolerated in terms of AE and other clinical and laboratory parameters at all dose levels. PK parameters of RPH-104 are summarized at Table 1 and Figure 1. Mean terminal elimination half-life (t1/2 ) was similar in all cohorts.  Initial results suggest linear PK for RPH-104 at all dose levels. PD analysis are ongoing. However, according to the PD analysis of the first 2 cohorts, administration of RPH-104 resulted in a decrease in Serum Amyloid A levels starting from the first hour post-dose in 20 mg cohort, and they remained suppressed throughout the study which may suggest the first biologic activity of RPH-104. Conclusion: RPH-104 was administered first time in humans, and it was considered safe and well tolerated following single dose SC administration at different dose levels. A linear PK was observed.



Disclosure: A. Gul, None; S. Ulker, None; R. S. Senturk, None; U. Onsel Turk, None; C. Gurgun, None, 5; Y. Lavrovsky, None, 3; M. Samsonov, None, 3; S. Ozen, None, 3; S. Altinel, None, 3.

To cite this abstract in AMA style:

Gul A, Ulker S, Senturk RS, Onsel Turk U, Gurgun C, Lavrovsky Y, Samsonov M, Ozen S, Altinel S. A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-first-in-human-phase-i-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-a-novel-anti-interleukin-1-biologic-agent-rph-104-in-healthy-subjects/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-first-in-human-phase-i-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-a-novel-anti-interleukin-1-biologic-agent-rph-104-in-healthy-subjects/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology